

IN THE SPECIFICATION:

Please amend the "CROSS-REFERENCES TO RELATED APPLICATIONS" section of the specification, originally presented at page 1, lines 5-6, to extend priority of the application to encompass each of the below-enumerated patent applications.

A1  
This application claims the priority benefit of U.S. Provisional Application No. 60/213,708, filed by Krempf et al. on June 23, 2000. The present application also claims the benefit of and is a continuation-in-part of U.S. Patent Application No. 09/291,894, filed April 13, 1999, which is a continuation-in-part of U.S. Patent Application No. 08/892,403, filed July 15, 1997, issued on November 30, 1999 as U.S. Patent No. 5,993,824, which is entitled to priority from U.S. Provisional Application Nos. 60/047,634, filed May 23, 1997; 60/046,141, filed May 9, 1997; and 60/021,773, filed July 15, 1996, each of which is incorporated herein by reference. The present application also claims the priority benefit of U.S. Patent Application No. 09/847,173, filed May 01, 2001, which is a divisional application of U.S. Patent Application No. 08/720,173, filed September 27, 1996, issued on July 24, 2001 as U.S. Patent No. 6,264,957, which is entitled to priority from U.S. Provisional Application No. 60/007,083, filed September 27, 1995, each of which is incorporated herein by reference.

Please amend the Abstract of the specification, originally presented at page 148, lines 4-20, to shorten the length as suggested by the Office as follows:

A2  
Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus ~~are infectious and attenuated in humans and other mammals. Gene-shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant RSV genome or antigenome wherein a gene or gene segment is shifted to a more promoter proximal or promoter distal position within the genome or antigenome compared to a wild-type position of the gene in the RSV gene map. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene, depending on the nature and degree of the positional shift. In one embodiment, expression of RSV glycoproteins are is upregulated by shifting one or more glycoprotein-~~

A2  
cont'd

encoding genes to a more promoter-proximal position. Genes of interest for manipulation to create gene position-shifted RSV include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment that may be part of a gene or extragenic. ~~A variety of additional~~ Additional mutations and nucleotide modifications are provided within the gene position-shifted RSV ~~of the invention~~ to yield desired phenotypic and structural effects.

---